:@0.914624:0.081813:0.920519:0.081813:0.920519:0.063369:0.914624:0.063369:0.005895
 :@0.884977:0.970453:0.890322:0.970453:0.890322:0.952432:0.884977:0.952432:0.005345
OD6  Molecular Characterization of LIC10280, a Novel :@0.242066:0.104825:0.833894:0.104825:0.833894:0.086058:0.242066:0.086058:0.018519:0.017185:0.013184:0.006617:0.017328:0.019828:0.013234:0.005284:0.013234:0.011901:0.013234:0.005284:0.013068:0.007926:0.006617:0.017185:0.013234:0.013234:0.007926:0.013115:0.011901:0.006617:0.013234:0.007998:0.005141:0.011901:0.013306:0.006617:0.005284:0.013044:0.013115:0.006617:0.013234:0.006522:0.006617:0.013234:0.006522:0.017185:0.013282:0.013234:0.013234:0.013163:0.013234:0.006617:0.006522:0.013234:0.006617:0.017185:0.013234:0.011901:0.013234:0.005284:0.006617
Putative Virulence Factor of Leptospira interrogans in :@0.314899:0.125687:0.881476:0.125687:0.881476:0.106920:0.314899:0.106920:0.015876:0.013234:0.006522:0.013234:0.006617:0.005284:0.011901:0.013234:0.006617:0.015805:0.005284:0.007926:0.013234:0.005189:0.013234:0.013234:0.011901:0.013234:0.006617:0.014472:0.013234:0.011973:0.006617:0.013044:0.007926:0.006617:0.013115:0.006617:0.006498:0.013234:0.013234:0.013234:0.006617:0.013234:0.011973:0.013234:0.005141:0.007926:0.013282:0.006617:0.005070:0.013234:0.006617:0.013234:0.007926:0.007926:0.013234:0.013234:0.013115:0.013234:0.011973:0.006617:0.005284:0.013234:0.006617
yeast model :@0.314899:0.146584:0.449652:0.146584:0.449652:0.127817:0.314899:0.127817:0.011901:0.013306:0.013115:0.011901:0.006617:0.006585:0.019828:0.013234:0.013234:0.013234:0.005179:0.006617
 :@0.906214:0.104825:0.912832:0.104825:0.912832:0.086058:0.906214:0.086058:0.006617
OD7  Knockdown of OTUB1 and OTUB2 Induces Cell Cycle   :@0.242066:0.173292:0.912832:0.173292:0.912832:0.154525:0.242066:0.154525:0.018519:0.017185:0.013184:0.006617:0.017328:0.015876:0.013234:0.013234:0.011806:0.011901:0.013306:0.013115:0.017185:0.013282:0.006617:0.013044:0.006617:0.006498:0.018519:0.014543:0.017185:0.015876:0.013234:0.006617:0.013234:0.013234:0.013234:0.006450:0.018519:0.014543:0.017185:0.015876:0.013234:0.006617:0.006522:0.013234:0.013139:0.013234:0.011901:0.013234:0.011901:0.006617:0.017090:0.013234:0.005284:0.005284:0.006617:0.017043:0.011901:0.012020:0.005141:0.013234:0.006617:0.014241:0.006617
Arrest and Modulates Cancer Regulatory Gene :@0.314899:0.194155:0.816566:0.194155:0.816566:0.175388:0.314899:0.175388:0.015876:0.007926:0.007926:0.013234:0.011901:0.006617:0.006498:0.013234:0.013234:0.013234:0.006617:0.019661:0.013234:0.013234:0.013234:0.005284:0.013282:0.006617:0.013044:0.011901:0.006617:0.017185:0.013234:0.013068:0.011901:0.013306:0.007926:0.006474:0.017185:0.013282:0.013115:0.013234:0.005284:0.013234:0.006617:0.013092:0.007831:0.011901:0.006617:0.018519:0.013234:0.013163:0.013234:0.006617
Expression in Hepatocellular Carcinoma Cells :@0.314899:0.214917:0.803463:0.214917:0.803463:0.196150:0.314899:0.196150:0.015876:0.011901:0.013234:0.007926:0.013234:0.011806:0.011901:0.005284:0.013234:0.013234:0.006522:0.005284:0.013092:0.006617:0.017185:0.013234:0.013234:0.013234:0.006617:0.013115:0.011901:0.013306:0.005284:0.005118:0.013234:0.005284:0.013234:0.007998:0.006617:0.017185:0.013115:0.007831:0.011901:0.005284:0.013282:0.013234:0.019685:0.013115:0.006617:0.017185:0.013234:0.005284:0.005284:0.011961:0.006617
OD8  In silico development of DNA aptamer against actin :@0.242066:0.241726:0.860410:0.241726:0.860410:0.222959:0.242066:0.222959:0.018519:0.017185:0.013184:0.006617:0.017328:0.006617:0.013234:0.006522:0.011901:0.005284:0.005284:0.005284:0.011997:0.013234:0.006617:0.013068:0.013234:0.011901:0.013234:0.005094:0.013234:0.013234:0.019828:0.013234:0.013234:0.006617:0.006617:0.013234:0.006522:0.006617:0.017043:0.017185:0.015876:0.006617:0.013234:0.013234:0.006546:0.013234:0.019828:0.013115:0.007926:0.006617:0.013234:0.013234:0.013234:0.005284:0.013163:0.011901:0.006617:0.006617:0.013234:0.011901:0.006617:0.005284:0.013234:0.006617
protein of E. histolytica :@0.314899:0.262488:0.560589:0.262488:0.560589:0.243721:0.314899:0.243721:0.013234:0.007974:0.013234:0.006617:0.013234:0.005284:0.013234:0.006617:0.013234:0.006498:0.006617:0.015757:0.006617:0.006498:0.013234:0.005284:0.011949:0.006617:0.013234:0.005094:0.011901:0.006617:0.005284:0.011901:0.013304:0.006617
 :@0.906214:0.241726:0.912832:0.241726:0.912832:0.222959:0.906214:0.222959:0.006617
OD9  A Case Report of a Novel De Novo FBN1 c.2342del :@0.242066:0.289297:0.866763:0.289297:0.866763:0.270530:0.242066:0.270530:0.018519:0.017185:0.013184:0.006617:0.017328:0.015876:0.006498:0.017185:0.013282:0.011901:0.013306:0.006472:0.017185:0.013282:0.013115:0.013115:0.007926:0.006617:0.006617:0.013234:0.006522:0.006617:0.013234:0.006522:0.017185:0.013282:0.011901:0.013234:0.005284:0.006498:0.017185:0.013282:0.006617:0.017043:0.013234:0.011901:0.013234:0.006522:0.014543:0.015876:0.017185:0.013234:0.006617:0.011901:0.006617:0.013092:0.013234:0.013234:0.013163:0.013234:0.013234:0.005165:0.006617
Leading to Premature Termination Codon in Marfan :@0.314899:0.310059:0.864219:0.310059:0.864219:0.291292:0.314899:0.291292:0.013234:0.013234:0.013234:0.013306:0.005141:0.013234:0.013234:0.006617:0.006546:0.013234:0.006617:0.015781:0.007831:0.013234:0.019828:0.013234:0.006617:0.013234:0.007831:0.013234:0.006617:0.014543:0.013234:0.007807:0.019828:0.005284:0.013234:0.013234:0.006617:0.005284:0.013234:0.013234:0.006546:0.017114:0.013234:0.013139:0.013234:0.013234:0.006617:0.005284:0.013234:0.006617:0.019733:0.013234:0.007974:0.006617:0.013044:0.013234:0.006617
Syndrome Patients :@0.314899:0.330922:0.522248:0.330922:0.522248:0.312155:0.314899:0.312155:0.015876:0.011901:0.013234:0.013139:0.007926:0.013282:0.019828:0.013234:0.006617:0.015757:0.013115:0.006617:0.005284:0.013234:0.013234:0.006522:0.011928:0.006617
 :@0.906214:0.289297:0.912832:0.289297:0.912832:0.270530:0.906214:0.270530:0.006617
OD10  Machine Learning-based Prostate Cancer Prediction :@0.242066:0.357630:0.873560:0.357630:0.873560:0.338863:0.242066:0.338863:0.018519:0.017185:0.013234:0.013063:0.006617:0.004215:0.019828:0.013234:0.011949:0.013234:0.005141:0.013234:0.013234:0.006617:0.013234:0.013115:0.013234:0.007926:0.013234:0.005284:0.013234:0.013308:0.007839:0.013234:0.013139:0.011901:0.013306:0.013234:0.006617:0.015638:0.007926:0.013282:0.011901:0.006617:0.013234:0.006617:0.013234:0.006403:0.017185:0.013282:0.013115:0.011901:0.013234:0.007926:0.006617:0.015757:0.007926:0.013282:0.013234:0.005141:0.011901:0.006617:0.005284:0.013234:0.013234:0.006617
Model: Integrating FTIR Spectra from Urinary EVs :@0.314899:0.378493:0.846938:0.378493:0.846938:0.359726:0.314899:0.359726:0.019828:0.013234:0.013234:0.013234:0.005284:0.006617:0.006522:0.006617:0.013234:0.006522:0.013234:0.013234:0.007926:0.013234:0.006522:0.005284:0.013234:0.013234:0.006617:0.014543:0.014543:0.006522:0.017185:0.006617:0.015686:0.013234:0.013234:0.011997:0.006617:0.007783:0.013234:0.006617:0.006522:0.007926:0.013282:0.019828:0.006403:0.017114:0.007926:0.005284:0.013234:0.013234:0.007926:0.011901:0.006617:0.015876:0.015781:0.011901:0.006617
with Clinical Profiles in Modeling :@0.314899:0.399355:0.660931:0.399355:0.660931:0.380588:0.314899:0.380588:0.017185:0.005284:0.006617:0.013234:0.006617:0.017185:0.005284:0.005284:0.013234:0.005141:0.011901:0.013306:0.005284:0.006403:0.015876:0.007926:0.013234:0.006617:0.005284:0.005284:0.013234:0.011901:0.006617:0.005284:0.013234:0.006546:0.019828:0.013092:0.013234:0.013234:0.005284:0.005284:0.013234:0.013222:0.006617
 :@0.906214:0.357630:0.912832:0.357630:0.912832:0.338863:0.906214:0.338863:0.006617
OD11  Expression Of TNFR2 AND KI-67 In Sporadic Young-:@0.242066:0.426097:0.877225:0.426097:0.877225:0.407330:0.242066:0.407330:0.018519:0.017185:0.013234:0.013063:0.006617:0.004215:0.015876:0.011901:0.013234:0.007926:0.013234:0.011806:0.011901:0.005284:0.013234:0.013234:0.006522:0.018376:0.006617:0.006498:0.014543:0.017185:0.014543:0.017281:0.013234:0.006617:0.015638:0.017114:0.017185:0.006617:0.015876:0.006552:0.007982:0.013234:0.013234:0.006617:0.006546:0.013234:0.006617:0.015781:0.013115:0.013234:0.007974:0.013234:0.013234:0.005165:0.011901:0.006617:0.015876:0.013234:0.013092:0.013234:0.013206:0.007926
Onset Crc In A Single Tertiary Center :@0.314899:0.446960:0.714951:0.446960:0.714951:0.428193:0.314899:0.428193:0.018519:0.013234:0.011901:0.013234:0.006546:0.006617:0.017185:0.007831:0.011901:0.006617:0.006617:0.013234:0.006522:0.015876:0.006498:0.015876:0.005284:0.013234:0.013234:0.005284:0.013234:0.006546:0.014543:0.013234:0.007926:0.006617:0.005141:0.013234:0.007974:0.011901:0.006474:0.017185:0.013282:0.013234:0.006617:0.013068:0.007972:0.006617
 :@0.314899:0.467823:0.321517:0.467823:0.321517:0.449056:0.314899:0.449056:0.006617
 :@0.906214:0.426097:0.912832:0.426097:0.912832:0.407330:0.906214:0.407330:0.006617
OD12  KRAS Mutation Profile of Colorectal Cancer Patients :@0.242066:0.494531:0.873645:0.494531:0.873645:0.475764:0.242066:0.475764:0.018519:0.017185:0.013234:0.013063:0.006617:0.004215:0.015876:0.017185:0.015876:0.015781:0.006617:0.019756:0.013234:0.006617:0.013234:0.006546:0.005284:0.013234:0.013234:0.006617:0.015781:0.007926:0.013282:0.006617:0.005284:0.005213:0.013234:0.006617:0.013234:0.006546:0.006617:0.017185:0.013234:0.005284:0.013115:0.007926:0.013234:0.011901:0.006617:0.013234:0.005284:0.006522:0.017185:0.013234:0.013234:0.011901:0.013139:0.007926:0.006617:0.015876:0.013234:0.006522:0.005284:0.013234:0.013234:0.006617:0.011901:0.006617
Diagnosed in Hospital Universiti Sains Malaysia :@0.314899:0.515394:0.823274:0.515394:0.823274:0.496627:0.314899:0.496627:0.017185:0.005284:0.013234:0.013234:0.013234:0.013092:0.011901:0.013306:0.013234:0.006617:0.005284:0.013234:0.006379:0.017185:0.013234:0.011901:0.013234:0.005284:0.006617:0.013234:0.005284:0.006522:0.017114:0.013234:0.005284:0.011901:0.013234:0.007926:0.011973:0.005284:0.006617:0.005213:0.006617:0.015757:0.013234:0.005284:0.013115:0.011901:0.006617:0.019685:0.013234:0.005284:0.013234:0.011901:0.011901:0.005284:0.013207:0.006617
 :@0.314899:0.536256:0.321517:0.536256:0.321517:0.517490:0.314899:0.517490:0.006617
 :@0.906214:0.494531:0.912832:0.494531:0.912832:0.475764:0.906214:0.475764:0.006617
OD13  Development of Electrochemical Aptasensor for the :@0.242066:0.562965:0.862910:0.562965:0.862910:0.544198:0.242066:0.544198:0.018519:0.017185:0.013234:0.013063:0.006617:0.004215:0.017185:0.013234:0.011901:0.013234:0.005284:0.013139:0.013234:0.019828:0.013234:0.013234:0.006450:0.006617:0.013234:0.006522:0.006617:0.015757:0.005284:0.013234:0.011949:0.006617:0.007926:0.013234:0.011901:0.013234:0.013068:0.019828:0.005284:0.011901:0.013234:0.005284:0.006617:0.015876:0.013234:0.006522:0.013115:0.011901:0.013234:0.013234:0.011901:0.013163:0.007926:0.006617:0.006617:0.013234:0.007926:0.006617:0.006498:0.013234:0.013234:0.006617
Detection of BipD Antigen of Burkholderia :@0.314899:0.583828:0.759868:0.583828:0.759868:0.565061:0.314899:0.565061:0.017185:0.013282:0.006617:0.013044:0.011901:0.006617:0.005284:0.013234:0.013234:0.006617:0.013234:0.006617:0.006498:0.015876:0.005284:0.013234:0.017185:0.006617:0.015781:0.013234:0.006617:0.005284:0.013234:0.013234:0.013234:0.006427:0.013234:0.006617:0.006522:0.015876:0.013234:0.007926:0.011973:0.013115:0.013234:0.005284:0.013234:0.013139:0.007831:0.005284:0.013234:0.006617
pseudomallei for Diagnostics Application :@0.314899:0.604589:0.748160:0.604589:0.748160:0.585823:0.314899:0.585823:0.013234:0.011973:0.013115:0.013234:0.013234:0.013234:0.019733:0.013234:0.005284:0.005284:0.013234:0.005141:0.006617:0.006498:0.013234:0.007974:0.006617:0.017185:0.005284:0.013234:0.013234:0.013139:0.013234:0.011973:0.006617:0.005070:0.011901:0.012020:0.006617:0.015757:0.013234:0.013234:0.005284:0.005165:0.011901:0.013306:0.006617:0.005284:0.013044:0.013428:0.006617
 :@0.906214:0.562965:0.912832:0.562965:0.912832:0.544198:0.906214:0.544198:0.006617
OD14  Enzymatic access to the rare ΔGlcA (α1→4) Glc 3, 6, :@0.242066:0.631399:0.881785:0.631399:0.881785:0.612632:0.242066:0.612632:0.018519:0.017185:0.013234:0.013063:0.006617:0.004215:0.015876:0.013234:0.011901:0.011901:0.019828:0.013234:0.006522:0.005284:0.011901:0.006617:0.013115:0.011901:0.011901:0.013115:0.011901:0.012020:0.006617:0.006498:0.013234:0.006617:0.006522:0.013234:0.013234:0.006617:0.007831:0.013115:0.007926:0.013282:0.006617:0.015757:0.018519:0.005284:0.011901:0.015876:0.006617:0.007783:0.013758:0.013234:0.023803:0.013234:0.007926:0.006617:0.018519:0.005094:0.011901:0.006617:0.013234:0.006617:0.006522:0.013234:0.006617:0.006617
N-sulfated heparin disaccharide, implications for :@0.314899:0.652161:0.827227:0.652161:0.827227:0.633394:0.314899:0.633394:0.017246:0.007839:0.011901:0.013306:0.005284:0.006617:0.013234:0.006498:0.013234:0.013234:0.006617:0.013092:0.013115:0.013234:0.013234:0.007998:0.005284:0.013234:0.006617:0.013234:0.005094:0.011901:0.013234:0.011782:0.011901:0.013234:0.013234:0.007926:0.005284:0.013234:0.013234:0.006617:0.006617:0.005213:0.019828:0.013234:0.005284:0.005118:0.011901:0.013234:0.006498:0.005284:0.013234:0.013234:0.011973:0.006617:0.006498:0.013234:0.007974:0.006617
heparin quality control :@0.314899:0.673023:0.554033:0.673023:0.554033:0.654256:0.314899:0.654256:0.013234:0.013234:0.013234:0.013234:0.007926:0.005284:0.013234:0.006617:0.013234:0.013092:0.013234:0.005284:0.005284:0.006617:0.011901:0.006617:0.011901:0.013139:0.013234:0.006617:0.007926:0.013234:0.005200:0.006617
 :@0.906214:0.631399:0.912832:0.631399:0.912832:0.612632:0.906214:0.612632:0.006617
Oral Presenter: Therapeutic :@0.251900:0.703797:0.571279:0.703797:0.571279:0.685030:0.251900:0.685030:0.018519:0.009259:0.013234:0.006617:0.006522:0.015876:0.009259:0.013234:0.013234:0.013234:0.014401:0.007831:0.013234:0.009259:0.007974:0.006617:0.014543:0.014543:0.013044:0.009259:0.013234:0.014543:0.013139:0.014401:0.007926:0.006617:0.013204:0.006617
OT1  Evaluating the Potential of Mesenchymal Stem Cells :@0.242066:0.732118:0.872169:0.732118:0.872169:0.713351:0.242066:0.713351:0.018529:0.014554:0.013097:0.006617:0.020036:0.015876:0.011901:0.013234:0.005284:0.013234:0.013234:0.006617:0.005284:0.013115:0.013234:0.006617:0.006522:0.013234:0.013234:0.006617:0.015805:0.013234:0.006617:0.013234:0.013234:0.006617:0.005284:0.013234:0.005284:0.006498:0.013234:0.006617:0.006522:0.019828:0.013234:0.011949:0.013115:0.013234:0.011901:0.013234:0.011806:0.019828:0.013092:0.005284:0.006617:0.015757:0.006617:0.013234:0.019828:0.006498:0.017185:0.013282:0.005284:0.005284:0.011901:0.006617
Expressing Erythropoietin for Treating Retinal :@0.314899:0.752980:0.800999:0.752980:0.800999:0.734213:0.314899:0.734213:0.015876:0.011901:0.013234:0.007926:0.013234:0.011806:0.011901:0.005284:0.013234:0.013234:0.006522:0.015876:0.007926:0.011901:0.006617:0.013115:0.007926:0.013282:0.013115:0.013234:0.005284:0.013234:0.006617:0.005284:0.013234:0.006546:0.006617:0.013234:0.007926:0.006617:0.014543:0.007783:0.013234:0.013234:0.006617:0.005284:0.013234:0.013234:0.006617:0.017066:0.013234:0.006617:0.005284:0.013234:0.013234:0.005284:0.006617
Dysfunction in a Rat Model :@0.314899:0.773843:0.605487:0.773843:0.605487:0.755076:0.314899:0.755076:0.017185:0.011901:0.011901:0.006617:0.013234:0.013139:0.011901:0.006617:0.005284:0.013234:0.013234:0.006617:0.005118:0.013234:0.006617:0.013234:0.006546:0.017185:0.013282:0.006617:0.006498:0.019828:0.013234:0.013234:0.013139:0.005335:0.006617
 :@0.906214:0.732118:0.912832:0.732118:0.912832:0.713351:0.906214:0.713351:0.006617
OT2  Therapeutic Potential of Stingless Bee Pollen: :@0.242066:0.800551:0.803427:0.800551:0.803427:0.781784:0.242066:0.781784:0.018529:0.014554:0.013097:0.006617:0.020036:0.014543:0.013234:0.013234:0.007926:0.013234:0.013234:0.013115:0.013234:0.006617:0.005284:0.011901:0.006427:0.015876:0.013234:0.006522:0.013234:0.013234:0.006617:0.005284:0.013234:0.005284:0.006546:0.013234:0.006617:0.006522:0.015876:0.006498:0.005284:0.013234:0.013234:0.005284:0.013234:0.011901:0.011901:0.006617:0.015805:0.013234:0.013234:0.006450:0.015876:0.013234:0.005284:0.005284:0.013234:0.013234:0.006546:0.006617
Enhancing DNA Methylation and Genomic Stability :@0.314899:0.821414:0.856389:0.821414:0.856389:0.802647:0.314899:0.802647:0.015876:0.013234:0.013234:0.013234:0.013115:0.011901:0.005284:0.013282:0.013234:0.006427:0.017114:0.017185:0.015876:0.006617:0.019828:0.013234:0.006498:0.013234:0.011973:0.005141:0.013234:0.006617:0.005284:0.013234:0.013234:0.006617:0.013234:0.013234:0.013234:0.006617:0.018328:0.013234:0.013234:0.013163:0.019828:0.005284:0.011901:0.006617:0.015876:0.006474:0.013234:0.013234:0.005284:0.005284:0.005284:0.006617:0.011927:0.006617
 :@0.906214:0.800551:0.912832:0.800551:0.912832:0.781784:0.906214:0.781784:0.006617
OT3  The role of ROS generation in the anticancer activity :@0.242066:0.848122:0.872194:0.848122:0.872194:0.829355:0.242066:0.829355:0.018529:0.014554:0.013097:0.006617:0.020036:0.014543:0.013234:0.013234:0.006617:0.007926:0.013234:0.005189:0.013234:0.006617:0.013234:0.006546:0.006617:0.017043:0.018519:0.015876:0.006499:0.013234:0.013234:0.013234:0.013234:0.007926:0.013234:0.006617:0.005284:0.013068:0.013234:0.006617:0.005284:0.013234:0.006522:0.006617:0.013234:0.013234:0.006546:0.013234:0.013234:0.006617:0.005284:0.011806:0.013234:0.013234:0.011901:0.013234:0.007926:0.006617:0.013092:0.011901:0.006617:0.005284:0.011901:0.005284:0.006617:0.011901:0.006617
of novel Schiff base compound in triple-negative :@0.314899:0.868985:0.827539:0.868985:0.827539:0.850218:0.314899:0.850218:0.013234:0.006617:0.006522:0.013234:0.013234:0.011997:0.013234:0.005284:0.006617:0.015781:0.011901:0.013234:0.005284:0.006498:0.006617:0.006498:0.013234:0.013234:0.011997:0.013234:0.006617:0.011782:0.013234:0.019828:0.013234:0.013139:0.013234:0.013234:0.013234:0.006617:0.005284:0.013234:0.006617:0.006498:0.007926:0.005284:0.013234:0.005284:0.013251:0.007982:0.013115:0.013234:0.013234:0.013234:0.006617:0.005284:0.011830:0.013234:0.006617
breast cancer :@0.314899:0.889848:0.465473:0.889848:0.465473:0.871081:0.314899:0.871081:0.013234:0.007974:0.013234:0.013139:0.011901:0.006617:0.006617:0.011901:0.013139:0.013234:0.011901:0.013234:0.007829:0.006617
 :@0.906214:0.848122:0.912832:0.848122:0.912832:0.829355:0.906214:0.829355:0.006617